Three active forms of aspartic proteinase from Mason-Pfizer monkey virus. 1998

A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
Department of Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.

Mason-Pfizer monkey virus (M-PMV) proteinase, released by the autocatalytic cleavage of Gag-Pro and Gag-Pro-Pol polypeptide precursors, catalyzes the processing of viral precursors to yield the structural proteins and enzymes of the virion. In retroviruses, usually only one proteolytically active form of proteinase exists. Here, we describe an unusual feature of M-PMV, the existence of three active forms of a retroviral proteinase with molecular masses of 17, 13, and 12 kDa as determined by mass spectroscopy. These forms arise in vitro by self-processing of a 26-kDa proteinase precursor. We have developed a process for isolation of each truncated product and demonstrate that all three forms display proteolytic activity. Amino acid analyses, as well as the determination of N- and C-terminal sequences, revealed that the N-termini of all three forms are identical, confirming that in vitro autoprocessing of the 17-kDa form occurs at the C-terminus to yield the truncated forms. The 17-kDa form and the newly described 13-kDa form of proteinase were identified in virions collected from the rhesus monkey CMMT cell line chronically infected with M-PMV, confirming that multiple forms exist in vivo.

UI MeSH Term Description Entries
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000882 Haplorhini A suborder of PRIMATES consisting of six families: CEBIDAE (some New World monkeys), ATELIDAE (some New World monkeys), CERCOPITHECIDAE (Old World monkeys), HYLOBATIDAE (gibbons and siamangs), CALLITRICHINAE (marmosets and tamarins), and HOMINIDAE (humans and great apes). Anthropoidea,Monkeys,Anthropoids,Monkey
D013058 Mass Spectrometry An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. Mass Spectroscopy,Spectrometry, Mass,Spectroscopy, Mass,Spectrum Analysis, Mass,Analysis, Mass Spectrum,Mass Spectrum Analysis,Analyses, Mass Spectrum,Mass Spectrum Analyses,Spectrum Analyses, Mass
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral
D016093 Mason-Pfizer monkey virus A species of BETARETROVIRUS isolated from mammary carcinoma in rhesus monkeys. It appears to have evolved from a recombination between a murine B oncovirus and a primate C oncovirus related to the baboon endogenous virus. Several serologically distinct strains exist. MPMV induces SIMIAN AIDS. SRV-1,SRV-2,Simian retrovirus 1,Simian retrovirus 2,SRV-3,Mason Pfizer monkey virus
D016282 Aspartic Acid Endopeptidases A sub-subclass of endopeptidases that depend on an ASPARTIC ACID residue for their activity. Aspartic Endopeptidases,Aspartyl Endopeptidases,Acid Endopeptidases, Aspartic,Endopeptidases, Aspartic Acid,Endopeptidases, Aspartyl

Related Publications

A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
January 1998, Advances in experimental medicine and biology,
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
July 2009, Journal of molecular biology,
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
June 1995, The Journal of biological chemistry,
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
January 2005, The FEBS journal,
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
February 1984, Lancet (London, England),
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
July 2001, Journal of biomolecular NMR,
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
February 1975, Journal of virology,
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
July 1992, Journal of virology,
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
August 1974, Journal of the National Cancer Institute,
A Zábranský, and M Andreánsky, and O Hrusková-Heidingsfeldová, and V Havlícek, and E Hunter, and T Ruml, and I Pichová
January 1982, Journal of cancer research and clinical oncology,
Copied contents to your clipboard!